Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | Phase 2 | terminated | Aug 23, 2023 | Anwaar Saeed | Terminated per directive from Bayer due to funding. | Funding |
| NCT05329870 | Does Genetic Susceptibility for Bleeding Affect Quantitative Faecal Immunochemical Test… | — | withdrawn | Apr 15, 2022 | University of Edinburgh | never started due to funding/staffing issues | Funding |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT02917759 | Liver and Biliary Tumor Tissue Registry | — | terminated | Sep 28, 2016 | Mayo Clinic | Lack of funding to support enrollment | Enrollment / accrual |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT04643405 | APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | terminated | Nov 25, 2020 | Ascentage Pharma Group Inc. | Company Strategy | Sponsor / business decision |
| NCT03275974 | Glutamine PET Imaging Colorectal Cancer | Phase 1 | terminated | Sep 8, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03844750 | Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and… | Phase 2 | terminated | Feb 18, 2019 | Chloe Atreya, MD, PhD | Sponsor decision | Sponsor / business decision |
| NCT04203160 | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With… | Phase 1 / Phase 2 | terminated | Dec 18, 2019 | University of Michigan Rogel Cancer Center | Loss of funding | Funding |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | Phase 2 | terminated | Mar 18, 2021 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | Phase 2 | withdrawn | Dec 16, 2025 | Massachusetts General Hospital | The pharmaceutical company is not moving forward with this intervention due to lack of efficacy. | Efficacy / futility |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage…(SURGIGAST) | Phase 3 | terminated | Feb 3, 2017 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT06420349 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | Phase 1 | terminated | May 20, 2024 | Mayo Clinic | study sponsor phasing out drug supply | Drug supply |
| NCT05044676 | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for…(IMMUNOCELL) | — | terminated | Sep 16, 2021 | Assistance Publique - Hôpitaux de Paris | Abandon of study | Other (stated, no rule matched) |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized… | Phase 2 / Phase 3 | terminated | Dec 28, 2021 | Peking University | Difficult to enroll participants | Enrollment / accrual |
| NCT05998447 | GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | Phase 2 | terminated | Aug 21, 2023 | Genome & Company | Sponsor decision | Sponsor / business decision |
| NCT01023412 | Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With…(IPOD-3) | N/A | terminated | Dec 2, 2009 | Société des Produits Nestlé (SPN) | interim review of the data indicated that the hypothesis put forth on the efficacy of a 3 day… | Efficacy / futility |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | Phase 2 | terminated | Mar 21, 2022 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05241210 | Real-Time Feedback (RTFB) to Improve Colonoscopy | N/A | suspended | Feb 15, 2022 | University of Minnesota | we are on hold and may restart depending on a manual followed by automated assessment of existing… | Other (stated, no rule matched) |
| NCT06199466 | A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With… | Phase 1 | terminated | Jan 10, 2024 | M.D. Anderson Cancer Center | \<75 % participation | Other (stated, no rule matched) |
| NCT05114213 | MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC(MASPAC) | Phase 2 | terminated | Nov 9, 2021 | Ludwig-Maximilians - University of Munich | Low accrual, close out in November 2025 | Enrollment / accrual |
| NCT05358704 | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer | Phase 2 | suspended | May 3, 2022 | Rutgers, The State University of New Jersey | no slots available | Other (stated, no rule matched) |
| NCT05427396 | A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004)… | Phase 1 | terminated | Jun 22, 2022 | Shanghai Junshi Bioscience Co., Ltd. | The trial was stopped early on the initiative of the sponsor on the basis of a change in the… | Safety / toxicity |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT04392050 | A Community-Based Educational Intervention to Improve Colorectal Cancer Screening | — | suspended | May 18, 2020 | Thomas Jefferson University | staffing | Other (stated, no rule matched) |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of… | Phase 1 | terminated | Mar 20, 2024 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT02885142 | Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic…(MUCEM) | N/A | terminated | Aug 31, 2016 | Assistance Publique Hopitaux De Marseille | difficulties to recruit all the patients | Enrollment / accrual |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | Phase 1 | terminated | Jun 14, 2022 | Colin D. Weekes, M.D., PhD | NIS793 is no longer being developed | Other (stated, no rule matched) |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab…(PRISM) | Phase 2 | withdrawn | May 29, 2025 | Weill Medical College of Cornell University | Drug and financial support not available for the study. | Funding |
| NCT04844970 | Anamorelin Study for Advanced Pancreatic Cancer | Phase 2 | terminated | Apr 14, 2021 | Lahey Clinic | The study closure was initiated by the financial sponsor and agreed upon by the site PI. The study… | Enrollment / accrual |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT05525286 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and…(CLAUDIO-01) | Phase 1 / Phase 2 | terminated | Sep 1, 2022 | SOTIO Biotech a.s. | Trial terminated by Sponsor based on benefit- risk reassessment | Other (stated, no rule matched) |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT07026916 | A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic… | Phase 2 | withdrawn | Jun 18, 2025 | Genfleet Therapeutics (Shanghai) Inc. | Adjustment of Product Development Strategy | Sponsor / business decision |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05246839 | Informed Choice - Compass | — | terminated | Feb 18, 2022 | Exact Sciences Corporation | Business decision to terminate the study early. Primary endpoint will not be assessed. | Sponsor / business decision |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following… | Phase 1 / Phase 2 | terminated | Oct 6, 2023 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or… | N/A | terminated | Aug 29, 2016 | University of Washington | Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.) | Enrollment / accrual |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | Phase 2 / Phase 3 | suspended | Sep 2, 2021 | Mirror Biologics, Inc. | Sponsor unable to fund | Funding |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | TriSalus Life Sciences, Inc. | The decision was made to terminate the study after the completion of Phase 1b enrollment and not… | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT06557278 | Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer(COMUNITY) | Phase 2 | withdrawn | Aug 16, 2024 | Mirror Biologics, Inc. | Redesign of protocol for primary end-point of overall survival | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 20, 2026source: clinicaltrials